EN DE
Watch Aevis Victoria SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Aevis Victoria SA (AEVS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Aevis Victoria SA stock CHF 3.32, price CHF 14.30, that is 76.8% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 4 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0478634105

AV Aevis Victoria SA logo Some data Nov 7, 2026

Aevis Victoria SA

AEVS · SW
Very expensive, weak quality

Our calculation puts a fair price 77% below what the stock costs today.

Generates free cash flow
Mixed Growth (revenue 5y +10.2 %/yr in CHF)
Some data
Fair value CHF 3.32 · Strongly overvalued (−76.8%)
Quality 37/100
Loss-making · -1.8% net margin (TTM)
High debt
Trails peers (1/12)
Narrow moat 20/100 · thin data
⚠ Small free float
Watch Aevis Victoria SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 20.68 CHF 11.39 Fair Value CHF 3.32 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range CHF 11.39 – CHF 20.68 · fair‑value band CHF 2.47 – CHF 4.95 · the CHF 14.30 price screens above the CHF 3.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.

Follow Aevis Victoria in your weekly email

Every Wednesday you see whether Aevis Victoria is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aevis Victoria SA engages in the healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. It operates through Hospitals, Hospitality, and Real Estate segments.

Show moreShow less

The company operates private hospitals, hotels, radiology institutes, pharmacy, urology center, health center, day clinics, spas, patient hotels, and golf courses. It also provides health management programs, lifestyle coaching and anti-aging cosmeceuticals under the Nescens brand.

In addition, the company offers ambulance, life sciences related services, medical home, physiotherapy, ophthalmology, sports medicine, medical radiation, stem cells, cosmetics, parking, cleaning services, sterilization, and IT related services.

Further, it owns real estate properties in the healthcare and hospitality sectors. The company was founded in 2006 and is headquartered in Fribourg, Switzerland. Aevis Victoria SA operates as a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.

Stock analysis

Aevis Victoria SA (AEVS) currently trades at CHF 14.30, while our model-based Fair Value estimate is CHF 3.32, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 4 models at a data quality of 93/100, which puts the data coverage at medium.

Scenario range: CHF 2.47 (bear) to CHF 4.95 (bull), the price of CHF 14.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aevis Victoria SA reported revenue of CHF 1.1B in FY2025 versus CHF 823M in FY2021, a compound +8.3%/yr. Reported net income was −CHF 20.1M in FY2025.

Key figures

Market cap CHF 1.2B Small · P/S ratio 1.16 · EPS (TTM) CHF −0.2300 · Net margin −1.8% · Return on equity −4.1% · Return on assets (EBIT) −2.0% (5-year average) · Operating margin 3.4% · Revenue (TTM) CHF 1.1B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −77%, AEVS screens richer than that median.

Fair Value models

Bear CHF 2.47 Fair Value CHF 3.32 Bull CHF 4.95
Price CHF 14.30 · Downside -76.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF n/a n/a CHF 1.51 77
Growth DCF n/a n/a CHF 0.5500 75
Owner Earnings n/a n/a CHF 5.05 73
All 4 models by family
DCF Models
FCF DCF n/a n/a CHF 1.51 77
Owner Earnings n/a n/a CHF 5.05 73
Asset-Based
NCAV (Graham) CHF 2.47 CHF 3.32 CHF 4.95 54
Growth DCF
Growth DCF n/a n/a CHF 0.5500 75

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 17
Do the profits arrive as real cash?
Financial strength 12
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 80
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 72
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.4% (2020) → −4.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+79.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +78.4% a year for the price.

AEVS screens overvalued: fair value 77% below the price. Compare with HCA Healthcare, Inc →

Compare Aevis Victoria SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks

Beats the industry median on 1/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −76.8% · Bottom 25%
Profitability
Return on assets −1.1% · Bottom 25%
Net margin (12 months) −1.8% · Bottom 25%
Operating margin (12 months) 3.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 1.9% · Below median
Balance sheet
Debt / equity 1.53× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 2.40× · Pricier than median
P/S (12 months) 1.16× · Cheaper than median
Price / free cash flow (fiscal year) 250.8× · Priciest 25%
EV/EBITDA 33.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)10 · sector 30
PAST (return on equity)0 · sector 32
HEALTH (low debt)23 · sector 90
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs AEVS
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs AEVS
DaVita Inc DVA $191.35 $218.90 +14% vs AEVS
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs AEVS
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs AEVS
Encompass Health Corporation EHC $137.54 $94.81 −31% vs AEVS
IHH Healthcare Berhad 5225 7.70 MYR 5.23 MYR −32% vs AEVS
Fresenius SE FRE €52.48 €34.77 −34% vs AEVS
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs AEVS
Dr. Sulaiman Al Habib Medical Services Group 4013 215.80 SAR 109.45 SAR −49% vs AEVS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aevis Victoria SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aevis Victoria SA Fair Value". https://www.fairvalue-calculator.com/stock/AEVS

Frequently asked questions

Is Aevis Victoria SA (AEVS) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of CHF 3.32 versus a price of CHF 14.30, about 77% lower (overvalued).
What is the fair value of AEVS?
Our model-based fair value for Aevis Victoria SA is CHF 3.32 (as of Nov 7, 2026), built from audited fundamentals. The current price: CHF 14.30.
What is the quality score of AEVS?
Aevis Victoria SA has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aevis Victoria SA (AEVS)?
Our model-based price target is the fair value of CHF 3.32 (as of Nov 7, 2026) from 4 valuation models. Cautious scenario CHF 2.47, optimistic scenario CHF 4.95. It is a calculation from audited fundamentals, not an analyst target.
What is the Aevis Victoria SA stock forecast for 2026?
Our models put fair value at CHF 3.32, about 77% lower versus a price of CHF 14.30 (overvalued). Cautious scenario CHF 2.47, optimistic scenario CHF 4.95. The calculation is refreshed regularly with new filings.
What is the revenue of Aevis Victoria SA (AEVS)?
Aevis Victoria SA reported trailing-twelve-month revenue of about CHF 1.1B (latest available figure, as of Nov 7, 2026).
What growth is priced into Aevis Victoria SA (AEVS)?
For today's price to be fair in a discounted-cash-flow model, Aevis Victoria SA would have to grow free cash flow by +79.4 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of AEVS use?
Our models discount Aevis Victoria SA at 11.0 %: a base by market capitalisation (small), country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aevis Victoria SA that is +79.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Aevis Victoria SA (AEVS) delivered so far?
Over the past 5 years revenue at Aevis Victoria SA grew +10.2 % a year. The price currently implies free-cash-flow growth of +79.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aevis Victoria SA (AEVS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Aevis Victoria SA (+79.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aevis Victoria SA (AEVS)?
The free-cash-flow yield on the price is 0.40 %: that much free cash flow Aevis Victoria SA produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aevis Victoria SA (AEVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aevis Victoria SA it is CHF 3.32 per share (as of Nov 7, 2026), against a price of CHF 14.30. It is the blended result of 4 valuation models in 3 families (DCF Models, Asset-Based, Growth DCF).
Is Aevis Victoria SA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, AEVS trades above its calculated fair value: price CHF 14.30, fair value CHF 3.32, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AEVS?
No. The price is what the market pays today (CHF 14.30); the fair value is what the company's own numbers justify (CHF 3.32). For Aevis Victoria SA the two are CHF 10.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aevis Victoria SA worth?
The market values Aevis Victoria SA at about CHF 1.2B (market capitalisation, as of Nov 7, 2026). Per share that is CHF 14.30; our models calculate a fair value of CHF 3.32 per share.
What do the bullish and bearish scenarios say about AEVS?
Our models span a range for Aevis Victoria SA: cautious scenario CHF 2.47, base CHF 3.32, optimistic CHF 4.95 per share (as of Nov 7, 2026, price CHF 14.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aevis Victoria SA (AEVS)?
Balance-sheet figures for Aevis Victoria SA (as of Nov 7, 2026): return on equity −4.1%, debt of 1.53 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is AEVS from its 52-week high?
Aevis Victoria SA trades at CHF 14.30, about 10% below its 52-week high of CHF 15.95 and 24% above the low of CHF 11.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 3.32 is for.
Which stocks are comparable to Aevis Victoria SA?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aevis Victoria SA stock attractive at the current price?
The data as of Nov 7, 2026: price CHF 14.30, calculated fair value CHF 3.32 (−77%), Quality Score 37/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AEVS calculated?
We run Aevis Victoria SA through 4 models from 3 families: DCF Models, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of CHF 3.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Aevis Victoria SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aevis Victoria SA (AEVS)?
The closing price on Nov 6, 2026 was CHF 14.30. Our model-based fair value is CHF 3.32, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aevis Victoria SA right now?
The price sits above even our optimistic bull case (CHF 4.95). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (CHF 2.47 to CHF 4.95) leaves room in how you read the outcome.

Key figures of Aevis Victoria SA

How large is the market capitalisation of Aevis Victoria SA (AEVS)?
The market capitalisation of Aevis Victoria SA is CHF 1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aevis Victoria SA (AEVS)?
The price-to-sales ratio of Aevis Victoria SA is 1.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aevis Victoria SA (AEVS)?
Earnings per share at Aevis Victoria SA are CHF −0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aevis Victoria SA (AEVS)?
The net margin of Aevis Victoria SA is −1.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aevis Victoria SA (AEVS)?
The return on equity (ROE) of Aevis Victoria SA is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aevis Victoria SA (AEVS)?
On an EBIT basis the return on assets of Aevis Victoria SA is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aevis Victoria SA (AEVS)?
The operating margin of Aevis Victoria SA is 3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aevis Victoria SA (AEVS)?
Revenue at Aevis Victoria SA is growing +1.9% versus a year earlier (3y avg +3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aevis Victoria SA (AEVS)?
Earnings per share at Aevis Victoria SA are growing +21.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Aevis Victoria SA (AEVS) carry?
The net debt of Aevis Victoria SA is CHF 921M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aevis Victoria SA in the live analysis

One click puts Aevis Victoria SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.